Accuray Incorporated (NASDAQ: ARAY) announced today that studies continue to demonstrate the unmatched flexibility of the cutting-edge TomoTherapy® System to treat, with precision and efficiency, a wide variety of indications of all complexities. More than 50 studies were presented during poster and oral sessions at the 36th Annual European Society for Radiotherapy & Oncology (ESTRO) Meeting in Vienna, Austria, May 5 – 9, 2017.
Study highlights include:
- A study evaluated hypofractionated intensity-modulated radiation therapy (IMRT) using TomoHelical™ in 121 postmastectomy patients with implant-based immediate breast reconstruction (IBR). Results demonstrated the TomoTherapy Treatment Planning System produced high-quality treatment plans providing optimal coverage of both the chest wall and supraclavicular region and sparing of all organs at risk. An additional analysis showed that the superior dosimetric outcomes provided treatment benefits. The side effect profile following treatment was favorable, with no patient experiencing greater than grade 2 acute toxicity. Rates of toxicity remained low in 85 patients with a median follow-up of 14.2 months. Clinicians at the European Institute of Oncology in Milan, Italy, conducted these two studies.
- A study of 68 patients with medically inoperable lung tumors found that image-guided stereotactic body radiation therapy (SBRT) delivered using TomoHelical provides an effective treatment option with minimal toxicity. The study was conducted at three Italian hospitals.
- A retrospective study evaluated the safety and efficacy of preoperative TomoHelical in combination with chemotherapy in patients with locally advanced rectal cancer (LARC). The three-year local control rate was 96.9% and treatment was well-tolerated. Clinicians at two Swiss hospitals conducted the research, which included the largest of this patient population to date.
- Toxicity and survival outcomes were reported for patients with high-risk prostate cancer enrolled in a phase 1-2 study evaluating hypofractionated TomoTherapy® and routine irradiation of pelvic lymph nodes. Five- and seven-year biochemical relapse-free survival (bRFS) was 87% and 80%, respectively; cancer-specific survival was 98% and 96%. Treatment was well-tolerated. Clinicians at the San Raffaele Scientific Institute in Milano, Italy conducted the study.
- Researchers at three European centers assessed the feasibility of boosting radiation dose to the dominant intraprostatic lesion (DIL) using the TomoTherapy System and found it to be a viable treatment option. Additionally, based on a dosimetric comparison of treatment plans, the system performed better than volumetric modulated arc radiotherapy (VMAT) in terms of achievable boost doses, target coverage and organ at risk sparing, and was similar in several aspects to intensity-modulated proton therapy (IMPT).
“The data presented at the ESTRO 36 meeting continue to show that the benefits of the TomoTherapy® System’s ring gantry platform and daily 3D image guidance in the treatment of a range of clinical indications.” said Fabienne Hirigoyenberry, VP Global Medical and Scientific Affairs of Accuray. “The Radixact™ System, the latest generation TomoTherapy platform, provides the same unrivaled delivery capabilities while giving clinicians the versatility to treat the broad spectrum of patients and disease types with the highest level of precision and increased speed and efficiency.”
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray’s leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading “Risk Factors” in the company’s report on Form 10-K, filed on August 24, 2016, the company’s reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company’s other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.